Altesa BioSciences closed a $75 million Series B round led by Forbion with participation from Sanofi to fund a Phase 2b study of vapendavir in COPD patients — a repositioning of a once‑failed rhinovirus antiviral toward preventing COPD exacerbations. CEO Brett Giroir and the investor syndicate emphasized targeting high‑risk populations to demonstrate clinical value. Sanofi’s involvement underscores pharma interest in respiratory antivirals that could reduce hospitalizations in chronic lung disease. The cash will also support global development and expand Altesa’s clinical operations.